Quesada J R, Alexanian R, Hawkins M, Barlogie B, Borden E, Itri L, Gutterman J U
Blood. 1986 Feb;67(2):275-8.
Thirty-two patients with multiple myeloma were treated with recombinant alpha-interferon clone A (rIFN alpha A) daily by intramuscular injection with an initial dose of 12 X 10(6) U/m2. Of 27 patients evaluable for response, tumor responses were obtained in seven of 14 previously untreated patients (50%) and two of 13 who had relapsed or failed prior chemotherapy (15%). In all patients who had tumor response, there was restoration from subnormal levels of serum immunoglobulins, an effect infrequently observed with chemotherapy. The median duration of tumor responses exceeded 14 months (range, 6 to 20). Moderate-to-severe fatigue was the predominant side effect and necessitated dose reductions in all patients. We conclude that treatment of early stages of multiple myeloma with rIFN alpha A is beneficial because of the substantial response rate and the improvement in the synthesis of serum immunoglobulins. rIFN alpha A has a potential role in combination with other agents in the treatment of multiple myeloma.
32例多发性骨髓瘤患者接受重组α干扰素克隆A（rIFNαA）治疗，每日肌肉注射，初始剂量为12×10⁶U/m²。在27例可评估疗效的患者中，14例既往未接受过治疗的患者中有7例（50%）出现肿瘤反应，13例曾复发或化疗失败的患者中有2例（15%）出现肿瘤反应。在所有出现肿瘤反应的患者中，血清免疫球蛋白水平从低于正常恢复，化疗很少观察到这种效果。肿瘤反应的中位持续时间超过14个月（范围为6至20个月）。中度至重度疲劳是主要的副作用，所有患者均需减少剂量。我们得出结论，rIFNαA治疗多发性骨髓瘤早期是有益的，因为有较高的反应率以及血清免疫球蛋白合成得到改善。rIFNαA在与其他药物联合治疗多发性骨髓瘤方面具有潜在作用。
